In regards to circulating tumor DNA (ctDNA), retrospective analyses have identified mutations such as XPO1 E571K that are present in the tumor and plasma and could become a useful genetic biomarker at diagnosis and for minimal residual disease (MRD) detection [97]. This evidence concerns the gene XPO1 and neoplasm.